Zhengda Tianqing's oral biased GLP-1 receptor agonist TQF3250 has submitted for clinical trials
On September 23, Chengda Tianqing Pharmaceutical Group's self-developed Class 1 innovative drug TQF3250's clinical trial application was accepted by the National Medical Products Administration, intended for the treatment of type 2 diabetes. In addition, the clinical trial protocol for TQF3250 also includes the exploration of weight loss indications
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments